Novel extended-release formulation of lovastatin by one-step melt granulation: In vitro and in vivo evaluation

被引:22
作者
Ochoa, L. [1 ]
Igartua, M. [1 ]
Hernandez, R. M. [1 ]
Gascon, A. R. [1 ]
Solinis, M. A. [1 ]
Pedraz, J. L. [1 ]
机构
[1] Univ Basque Country UPV EHU, Fac Pharm, Lab Pharm & Pharmaceut Technol, Vitoria, Spain
关键词
Lovastatin; Beagle dog; Melt granulation; Extended release; High-shear mixer; COENZYME-A REDUCTASE; HYDROPHILIC MATRIX TABLETS; DRUG-RELEASE; WEIBULL FUNCTION; DOSAGE FORMS; PHARMACOKINETICS; FOOD; INHIBITORS; DISSOLUTION; DELIVERY;
D O I
10.1016/j.ejpb.2010.11.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to apply a one-step melt granulation method to develop an extended-release formulation of lovastatin (LOV-ER). We prepared a formulation using PEG 6000 as binder agent in a laboratory scale high-shear mixer. In vitro dissolution studies showed that the release of the drug from the new formulation followed a zero-order kinetic with no differences in the release profile with either the pH media or the agitation rate. The pharmacokinetic of lovastatin and its metabolite lovastatin acid was evaluated after the administration of the new formulation to Beagle dogs in fasted conditions and after a high-fat meal, and compared to the marketed formulation Altoprev (R). After the administration of LOV-ER, extended plasma profiles of lovastatin and its active metabolite were achieved in both fasted conditions and after the high-fat meal. Plasma levels of lovastatin and lovastatin acid were always higher when the LOV-ER formulation was administered with the high-fat meal. A high variability in plasma levels and pharmacokinetic parameters was obtained, being this variability higher when the formulation was administered under fasting conditions. Our results suggest that there is an increase in lovastatin bio-availability when the formulation is administered after the high-fat meal. When we compare LOV-ER and Altoprev (R), both administered after the high-fat meal, we found significant differences (p < 0.05) in C(max) of lovastatin and in AUC(0-infinity) and MRT of lovastatin acid. No differences were detected between both formulations in fasting conditions. In this regard, the high-fat meal seems to increase the absorption extent of lovastatin from LOV-ER formulation and to delay the absorption rate of the drug from Altoprev (R). In conclusion, we developed a lovastatin formulation that provided extended plasma levels that confirm that one-step melt granulation in high-shear mixer could be an easy and cost-effective technique for extended-release formulation development. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:306 / 312
页数:7
相关论文
共 48 条
[1]   Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food [J].
Abrahamsson, B ;
Alpsten, M ;
Bake, B ;
Jonsson, UE ;
Eriksson-Lepkowska, M ;
Larsson, A .
JOURNAL OF CONTROLLED RELEASE, 1998, 52 (03) :301-310
[2]   Investigation of prandial effects on hydrophilic matrix tablets [J].
Abrahamsson, B ;
Roos, K ;
Sjögren, J .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (06) :765-771
[3]   DISCOVERY, BIOCHEMISTRY AND BIOLOGY OF LOVASTATIN [J].
ALBERTS, AW .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (15) :J10-J15
[4]  
*ANDRX LAB, 2002, ALT TM LOV EXT REL T
[5]  
[Anonymous], WINN 4 1
[6]  
[Anonymous], 1995, INT C HARM TECHN REQ
[7]   Excipient-excipient interaction in the design of sustained-release theophylline tablets: In vitro and in vivo evaluation [J].
Bayomi, MA ;
Al-Suwayeh, SA ;
El-Helw, ARM .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2001, 27 (06) :499-506
[8]   Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery [J].
Benet, LZ ;
Wu, CY ;
Hebert, MF ;
Wacher, VJ .
JOURNAL OF CONTROLLED RELEASE, 1996, 39 (2-3) :139-143
[9]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[10]  
Colombo P., 2000, Handbook of Pharmaceutical Controlled Release Technology, P183